Target intelligence / Profile preview

Pancreatic lipase and gastric lipase

Molecular classification
Enzyme, Hydrolase, Alpha/beta-hydrolase fold enzyme
01

Overview

Pancreatic and gastric lipases are key digestive enzymes responsible for the breakdown of dietary fats. Pancreatic lipase is secreted by the pancreas into the small intestine where it catalyzes the hydrolysis of triglycerides into monoglycerides and free fatty acids. This process requires bile salts for emulsification and colipase as a cofactor. Gastric lipase is secreted by chief cells in the stomach; it initiates lipid digestion under acidic conditions before chyme enters the small intestine. Both enzymes belong to distinct gene families but share an alpha/beta-hydrolase fold structure with a catalytic triad at their active site. Deficiencies or dysfunctions in these enzymes can result in malabsorption syndromes or contribute to diseases like pancreatitis. Pharmacological inhibition—most notably by drugs like orlistat—targets these enzymes therapeutically to reduce fat absorption as an anti-obesity strategy but may cause gastrointestinal side effects due to unabsorbed fats[1][4][5][6].

Other names
Pancreatic triacylglycerol lipase (for pancreatic lipase)Steapsin (for pancreatic lipase)PTL or PNLIP (abbreviations for pancreatic lipase)Gastric acid-stable triacylglycerol hydrolase (for gastric lipase)
02

Mechanism of action

Inhibition of enzymatic hydrolysis of dietary triglycerides in the gastrointestinal tract[5]

03

Biological functions

Digestion of dietary fatsHydrolysis of triglycerides to free fatty acids and glycerolAbsorption of fat-soluble vitamins
04

Disease associations

Acute pancreatitisChronic pancreatitisExocrine pancreatic insufficiencyObesity (as a therapeutic target)Malabsorption syndromes
05

Safety considerations

Inhibition can cause gastrointestinal side effects such as steatorrhea, diarrhea, and impaired absorption of fat-soluble vitamins[7]Long-term inhibition may lead to deficiencies in vitamins A, D, E, K
06

Interacting drugs

Orlistat (pancreatic lipase inhibitor)[5]
07

Biomarkers

Serum pancreatic lipase concentration is used as a biomarker for acute pancreatitis diagnosis[5]

Beyond the preview

Go deeper on Pancreatic lipase and gastric lipase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pancreatic lipase and gastric lipase.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call